Bone Tumors — Clinical and Radiologic Investigation

  • F. R. Eilber
  • E. Caulkins


Malignant neoplasms of bone are rare. Their estimated annual incidence is less than one case per 100,000 population, but the incidence of these bone cancers is age related. They constitute approximately 5% of all malignant tumors in young persons under 18 years of age, and reach a peak incidence of 8% of all cancers in the age group of 15–19 years. Their incidence declines to only a fraction of l% of all malignant neoplasms after the age of 30. Osteosarcoma constitutes 40% of these tumors. Chondrosarcoma represents 20%, Ewing’s sarcoma 12%, and fibrosarcoma 5%. In the peak age group, ie, ages 12–18 years, 60% of the bone cancers are osteosarcoma and 30% are Ewing’s sarcoma. In the 30–60 year age group, the most common primary malignant tumor of bone is chondrosarcoma.


Bone Tumor Giant Cell Tumor Bone Cancer Alkaline Phosphatase Level Malignant Bone Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. l.
    Bertelsen, C.A., Sondak, V.K., Mann, B.D., Korn, E.L., Morton, D.L., and Kern, D.H.: Chemosensitivity testing of human solid tumors- A review of 1582 assays with 263 clinical correlations. Cancer 1983, in press.Google Scholar
  2. 2.
    Chuang, V.P., Charnsangavey, C., Soo, C.S., Wallace, S., Benjamin, R.S., and Jaffe, N.: Radiographic and angiographic changes of osteosarcoma following intraarterial chemotherapy. Proc. Roent. Rad. A251, 1982.Google Scholar
  3. 3.
    Dahlin, D.C., and Coventry, M.B.: Osteosarcoma: a study of six hundred cases. J. Bone Joint Surg. 49, 101, 1967.PubMedGoogle Scholar
  4. 4.
    Glaubiger, D.L., Makuch, R., Schwarz, J., Levine, A., and Johnson, R.E.: Determination of prognostic factors and their influence on therapeutic results in patients with Ewing’s sarcoma. Cancer 45, 2213, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    Hudson, T.M., Haas, G., Enneking, W.F., and Hawkins, L.: Angiography in the management of musculoskeletal tumors. Surg. Gynecol. Obstet. 141, 11, 1975.PubMedGoogle Scholar
  6. 6.
    Huth, J.F., Gupta, R.K., Eilber, F.R., and Morton, D.L.: A prospective postoperative evaluation of urinary tumor-associated antigens in sarcoma patients: correlation with disease recurrence. Cancer 1983, in press.Google Scholar
  7. 7.
    Huth, J.F., Gupta, R.K., and Morton, D.L.: Sequential analysis of urinary antigen(s) in sarcoma patients. Surg. Forum 30, 150, 1979.PubMedGoogle Scholar
  8. 8.
    Lange, T.: Personal communication, 1983.Google Scholar
  9. 9.
    Levine, A.M., and Rosenberg, S.A.: Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. Cancer 44, 2291, 1979.PubMedCrossRefGoogle Scholar
  10. 10.
    Mueller, P.R., Wittenberg, J., Ferrucci, J., Murray, W.T., Mankin, H., and Shiller, A.: CT scanning in bone and soft-tissue tumors. J. Comput. Asst. Tomogr. 3, 570, 1979.CrossRefGoogle Scholar
  11. 11.
    Osbourne, R.: Differential radiologic diagnosis of bone tumor. CA 24, 194, 1974.CrossRefGoogle Scholar
  12. 12.
    Parker, B.R., and Marglin, S.I.: Evaluation of full-lung tomography in children with newly diagnosed bone and soft-tissue sarcoma. Clin. Res. 26, 196A, 1978.Google Scholar
  13. 13.
    Pritchard, D.: Personal communication, 1982.Google Scholar
  14. 14.
    Rikitake, T., Tateno, Y., and Arimizu, N.: Osteosarcomas in 18F bone positron scintigram - Comparative study with 99MTC-pyrophosphate. Nippon Igaku Hoshasen Gakkai Zoshi 39, 620, 1979.Google Scholar
  15. 15.
    Thorpe, W.P., Reilly, J.J., and Rosenberg, S.A.: Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 43, 2178, 1979.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • F. R. Eilber
  • E. Caulkins

There are no affiliations available

Personalised recommendations